CHF261.90
0.15% today
SIX Swiss Exchange, Apr 25, 05:31 pm CET
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Roche Stock price

CHF262.30
-41.90 13.77% 1M
-17.50 6.25% 6M
+6.80 2.66% YTD
+40.10 18.05% 1Y
-102.00 28.00% 3Y
-85.15 24.51% 5Y
-14.30 5.17% 10Y
SIX Swiss Exchange, Closing price Thu, Apr 24 2025
+4.20 1.63%
ISIN
CH0012032048
Symbol
ROG
Index
Sector
Industry

Key metrics

Market capitalization CHF208.63b
Enterprise Value CHF232.06b
P/E (TTM) P/E ratio 25.24
EV/FCF (TTM) EV/FCF 14.83
EV/Sales (TTM) EV/Sales 3.84
P/S ratio (TTM) P/S ratio 3.45
P/B ratio (TTM) P/B ratio 6.57
Dividend yield 3.70%
Last dividend (FY24) CHF9.70
Revenue growth (TTM) Revenue growth 3.03%
Revenue (TTM) Revenue CHF60.50b
EBIT (operating result TTM) EBIT CHF17.61b
Free Cash Flow (TTM) Free Cash Flow CHF15.65b
EPS (TTM) EPS CHF10.39
P/E forward 14.04
P/S forward 3.25
EV/Sales forward 3.62
Show more

Create a Free Account to create an Roche alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Roche Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Roche forecast:

12x Buy
48%
9x Hold
36%
4x Sell
16%

Analyst Opinions

25 Analysts have issued a Roche forecast:

Buy
48%
Hold
36%
Sell
16%

Financial data from Roche

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
60,495 60,495
3% 3%
100%
- Direct Costs 16,082 16,082
2% 2%
27%
44,413 44,413
4% 4%
73%
- Selling and Administrative Expenses 10,335 10,335
5% 5%
17%
- Research and Development Expense 13,042 13,042
1% 1%
22%
21,036 21,036
6% 6%
35%
- Depreciation and Amortization 3,423 3,423
1% 1%
6%
EBIT (Operating Income) EBIT 17,613 17,613
8% 8%
29%
Net Profit 8,277 8,277
28% 28%
14%

In millions CHF.

Don't miss a Thing! We will send you all news about Roche directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roche Stock News

Negative
Seeking Alpha
about 2 hours ago
Roche's Q1 revenues beat Street consensus, but key growth products underperformed, making the beat less appealing. Mid-sized products like Phesgo, Xolair, and Polivy drove the revenue beat, compensating for the underperformance of larger products. The diagnostics division faced pricing headwinds in China, impacting overall performance, but other geographies helped offset the decline and resulte...
Neutral
GlobeNewsWire
about 11 hours ago
Basel, 25 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil).1 The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza reduced the odds of untreated household members contract...
Neutral
Business Wire
about 11 hours ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil). The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza r...
More Roche News

Company Profile

Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Thomas Schinecker
Employees 103,249
Founded 1896
Website www.roche.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today